COVID-19 Vaccine: Critical Questions with Complicated Answers |
Haidere, Mohammad Faisal
(Department of Soil, Water and Environment, University of Dhaka)
Ratan, Zubair Ahmed (School of Health & Society, University of Wollongong) Nowroz, Senjuti (Department of Chemistry, University of Dhaka) Zaman, Sojib Bin (Department of Medicine, School of Clinical Sciences, Monash University) Jung, You-Jung (Biological Resources Utilization Department, National Institute of Biological Resources) Hosseinzadeh, Hassan (School of Health & Society, University of Wollongong) Cho, Jae Youl (Department of Integrative Biotechnology, and Biomedical Institute for Convergence at SKKU (BICS), Sungkyunkwan University) |
1 | Kim, H. W., Canchola, J. G., Brandt, C. D., Pyles, G., Chanock, R. M., Jensen, K. and Parrott, R. H. (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422-434. DOI |
2 | Kimmel, S. R. (2002) Vaccine adverse events: separating myth from reality. Am. Fam. Physician 66, 2113-2120. |
3 | Korber, B., Fischer, W., Gnanakaran, S. G., Yoon, H., Theiler, J., Abfalterer, W., Foley, B., Giorgi, E. E., Bhattacharya, T., Parker, M. D., Partridge, D. G., Evans, C. M., Freeman, T. M., de Silva, T. I.; on behalf of the Sheffield COVID-19 Genomics Group, LaBranche, C. C. and Montefiori, D. C. (2020) Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv doi: 10.1016/j.cell.2020.06.043. DOI |
4 | Koyama, T., Weeraratne, D., Snowdon, J. L. and Parida, L. (2020) Emergence of drift variants that may affect COVID-19 vaccine development and antibody treatment. Pathogens 9, 324. DOI |
5 | Le Houezec, D. (2014) Evolution of multiple sclerosis in France since the beginning of hepatitis B vaccination. Immunol. Res. 60, 219-225. DOI |
6 | Le, T. T., Cramer, J. P., Chen, R. and Mayhew, S. (2020) Evolution of the COVID-19 vaccine development landscape. Nat. Rev. Drug Discov. 19, 667-668. DOI |
7 | Liu, L., Wei, Q., Lin, Q., Fang, J., Wang, H., Kwok, H., Tang, H., Nishiura, K., Peng, J., Tan, Z., Wu, T., Cheung, K. W., Chan, K. H., Alvarez, X., Qin, C., Lackner, A., Perlman, S., Yuen, K. Y. and Chen, Z. (2019) Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 4, e123158. DOI |
8 | Xiao, A. T., Gao, C. and Zhang, S. (2020) Profile of specific antibodies to SARS-CoV-2: the first report. J. Infect. 81, 147-178. DOI |
9 | Yazdanpanah, F., Hamblin, M. R. and Rezaei, N. (2020) The immune system and COVID-19: friend or foe? Life Sci. 256, 117900. DOI |
10 | Zepp, F. (2010) Principles of vaccine design-lessons from nature. Vaccine 28, C14-C24. DOI |
11 | Zhang, C., Zhao, Y. X., Zhang, Y. H., Zhu, L., Deng, B. P., Zhou, Z. L., Li, S. Y., Lu, X. T., Song, L. L., Lei, X. M., Tang, W. B., Wang, N., Pan, C. M., Song, H. D., Liu, C. X., Dong, B., Zhang, Y. and Cao, Y. (2010) Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells. Proc. Natil. Acad. Sci. U.S.A. 107, 15886-15891. DOI |
12 | Zhou, Z., Ren, L., Zhang, L., Zhong, J., Xiao, Y., Jia, Z., Guo, L., Yang, J., Wang, C., Jiang, S., Yang, D., Zhang, G., Li, H., Chen, F., Xu, Y., Chen, M., Gao, Z., Yang, J., Dong, J., Liu, B., Zhang, X., Wang, W., He, K., Jin, Q., Li, M. and Wang, J. (2020) Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe 27, 883-890.e2. DOI |
13 | Schonberger, L. B., Bregman, D. J., Sullivan-Bolyai, J. Z., Keenlyside, R. A., Ziegler, D. W., Retailliau, H. F., Eddins, D. L. and Bryan, J. A. (1979) Guillain-Barre syndrome following vaccination in the national influenza immunization program, United States, 1976-1977. Am. J. Epidemiol. 110, 105-123. DOI |
14 | Shereen, M. A., Khan, S., Kazmi, A., Bashir, N. and Siddique, R. (2020) COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J. Adv. Res. 24, 91-98. DOI |
15 | Corman, V. M., Muth, D., Niemeyer, D. and Drosten, C. (2018). Hosts and sources of endemic human coronaviruses. In Advances in Virus Research, Vol. 100, pp. 163-188. Elsevier. |
16 | Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C. and Garry, R. F. (2020) The proximal origin of SARS-CoV-2. Nat. Med. 26, 450-452. DOI |
17 | Callow, K., Parry, H., Sergeant, M. and Tyrrell, D. (1990) The time course of the immune response to experimental coronavirus infection of man. Epidemiol. Infect. 105, 435-446. DOI |
18 | Clem, A. S. (2011) Fundamentals of vaccine immunology. J. Glob. Infect. Dis. 3, 73-78. DOI |
19 | Cui, W., Fan, Y., Wu, W., Zhang, F., Wang, J. y. and Ni, A. p. (2003) Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome. Clin. Infect. Dis. 37, 857-859. DOI |
20 | Du, Z., Zhu, F., Guo, F., Yang, B. and Wang, T. (2020) Detection of antibodies against SARS-CoV-2 in patients with COVID-19. J. Med. Virol. doi: 10.1002/jmv.25820 [Online ahead of print]. DOI |
21 | Duffy, J., Weintraub, E., Vellozzi, C. and DeStefano, F. (2014) Narcolepsy and influenza A (H1N1) pandemic 2009 vaccination in the United States. Neurology 83, 1823-1830. DOI |
22 | Ewer, K., Sebastian, S., Spencer, A. J., Gilbert, S., Hill, A. V. and Lambe, T. (2017) Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. Hum. Vaccin. Immunother. 13, 3020-3032. DOI |
23 | Partinen, M., Saarenpaa-Heikkila, O., Ilveskoski, I., Hublin, C., Linna, M., Olsen, P., Nokelainen, P., Alen, R., Wallden, T., Espo, M., Rusanen, H., Olme, J., Satila, H., Arikka, H., Kaipainen, P., Julkunen, I. and Kirjavainen, T. (2012) Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 7, e33723. DOI |
24 | Long, Q. X., Tang, X. J., Shi, Q. L., Li, Q., Deng, H. J., Yuan, J., Hu, J. L., Xu, W., Zhang, Y., Lv, F. J., Su, K., Zhang, F., Gong, J., Wu, B., Liu, X. M., Li, J. J., Qiu, J. F., Chen, J. and Huang, A. L. (2020b) Clinical and immunological assessment of asymptomatic SARSCoV-2 infections. Nat. Med. 26, 1200-1204. DOI |
25 | Long, Q. X., Liu, B. Z., Deng, H. J., Wu, G. C., Deng, K., Chen, Y. K., Liao, P., Qiu, J. F., Lin, Y., Cai, X. F., Wang, D. Q., Hu, Y., Ren, J. H., Tang, N., Xu, Y. Y., Yu, L. H., Mo, Z., Gong, F., Zhang, X. L., Tian, W. G., Hu, L., Zhang, X. X., Xiang, J. L., Du, H. X., Liu, H. W., Lang, C. H., Luo, X. H., Wu, S. B., Cui, X. P., Zhou, Z., Zhu, M. M., Wang, J., Xue, C. J., Li, X. F., Wang, L., Li, Z. J., Wang, K., Niu, C. C., Yang, Q. J., Tang, X. J., Zhang, Y., Liu, X. M., Li, J. J., Zhang, D. C., Zhang, F., Liu, P., Yuan, J., Li, Q., Hu, J. L., Chen, J. and Huang, A. L. (2020a) Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845-848. DOI |
26 | Morris, S. J., Sebastian, S., Spencer, A. J. and Gilbert, S. C. (2016) Simian adenoviruses as vaccine vectors. Fut. Virol. 11, 649-659. DOI |
27 | Moser, M. and Leo, O. (2010) Key concepts in immunology. Vaccine 28, C2-C13. DOI |
28 | Mullard, A. (2020) COVID-19 vaccine development pipeline gears up. Lancet 395, 1751-1752. DOI |
29 | Naismith, R. T. and Cross, A. H. (2004) Does the hepatitis B vaccine cause multiple sclerosis? Neurology 63, 772-773. DOI |
30 | Offit, P. A. (2005) The Cutter incident, 50 years later. N. Engl. J. Med. 352, 1411-1412. DOI |
31 | Gopinathan, U., Peacocke, E., Gouglas, D., Ottersen, T. and Rottingen, J. A. (2020) R&D for emerging infectious diseases of epidemic potential: sharing risks and benefits through a new coalition. In Infectious Diseases in the New Millennium, pp. 137-165. Springer. |
32 | Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., BelijRammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., Dold, C., Faust, S. N., Finn, A., Flaxman, A. L., Hallis, B., Heath, P., Jenkin, D., Lazarus, R., Makinson, R., Minassian, A. M., Pollock, K. M., Ramasamy, M., Robinson, H., Snape, M., Tarrant, R., Voysey, M., Green, C., Douglas, A. D., Hill, A. V. S., Lambe, T., Gilbert, S. C. and Pollard, A. J.; Oxford COVID Vaccine Trial Group (2020) Safety and immunogenicity of the ChAdOx1 nCoV19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396, 467-478. DOI |
33 | Gaebler, C. and Nussenzweig, M. C. (2020) All eyes on a hurdle race for a SARS-CoV-2 vaccine. Nature 586, 501-502. DOI |
34 | Gerdil, C. (2003) The annual production cycle for influenza vaccine. Vaccine 21, 1776-1779. DOI |
35 | Guo, Y. R., Cao, Q. D., Hong, Z. S., Tan, Y. Y., Chen, S. D., Jin, H. J., Tan, K. S., Wang, D. Y. and Yan, Y. (2020) The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status. Mil. Med. Res. 7, 11. DOI |
36 | Hotez, P. J., Corry, D. B. and Bottazzi, M. E. (2020) COVID-19 vaccine design: the Janus face of immune enhancement. Nat. Rev. Immunol. 20, 347-348. DOI |
37 | Peeri, N. C., Shrestha, N., Rahman, M. S., Zaki, R., Tan, Z., Bibi, S., Baghbanzadeh, M., Aghamohammadi, N., Zhang, W. and Haque, U. (2020) The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int. J. Epidemiol. 49, 717-726. DOI |
38 | Phan, T. (2020) Genetic diversity and evolution of SARS-CoV-2. Infect. Genet. Evol. 81, 104260. DOI |
39 | Ratan, Z. A., Hosseinzadeh, H., Runa, N. J., Uddin, B. M. M., Haidere, M. F., Sarker, S. K. and Zaman, S. B. (2020) Novel Coronavirus: a new challenge for medical scientist? Bangladesh J. Infect. Dis. 7, S58-S60. |
40 | Hodgson, S. H., Mansatta, K., Mallett, G., Harris, V., Emary, K. R. and Pollard, A. J. (2020) What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect. Dis. doi: 10.1016/S1473-3099(20)30773-8 [Online ahead of print]. DOI |
41 | Weingartl, H., Czub, M., Czub, S., Neufeld, J., Marszal, P., Gren, J., Smith, G., Jones, S., Proulx, R, Deschambault, Y., Grudeski, E., Andonov, A., He, R., Li, Y., Copps, J., Grolla, A., Dick, D., Berry, J., Ganske, S., Manning, L. and Cao, J. (2004) Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol. 78, 12672-12676. DOI |
42 | Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G. F. and Tan, W.; China Novel Coronavirus Investigating and Research Team (2020) A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727-733. DOI |
43 | Houser, K. V., Broadbent, A. J., Gretebeck, L., Vogel, L., Lamirande, E. W., Sutton, T., Bock, K. W., Minai, M., Orandle, M., Moore, I. N. and Subbarao, K. (2017) Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody. PLoS Pathog. 13, e1006565. DOI |
44 | Huisman, W., Martina, B., Rimmelzwaan, G., Gruters, R. and Osterhaus, A. (2009) Vaccine-induced enhancement of viral infections. Vaccine 27, 505-512. DOI |
45 | Institute of Medicine (US) Immunization Safety Review Committe (2002) Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer (K. Stratton, D. A. Almario and M. C. McCormick Eds). National Academies Press (US), Washington DC. |
46 | Tetro, J. A. (2020) Is COVID-19 receiving ADE from other coronaviruses? Microbes Inf. 22, 72-73. DOI |
47 | van Riel, D. and de Wit, E. (2020) Next-generation vaccine platforms for COVID-19. Nat. Mater. 19, 810-812. DOI |
48 | Vickers, C., Hales, P., Kaushik, V., Dick, L., Gavin, J., Tang, J., Godbout, K., Parsons, T., Baronas, E., Hsieh, F., Acton, S., Patane, M., Nichols, A. and Tummino, P. (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 277, 14838-14843. DOI |
49 | Wilder-Smith, A. (2020) Dengue vaccine development: status and future. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 63, 40-44. DOI |
50 | World Health Organization (2020) Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. In Coronavirus Disease (COVID-19) Situation Reports, Vol. 2020. World Health Organization: WHO. |
51 | Ascherio, A., Zhang, S. M., Hernan, M. A., Olek, M. J., Coplan, P. M., Brodovicz, K. and Walker, A. M. (2001) Hepatitis B vaccination and the risk of multiple sclerosis. N. Engl. J. Med. 344, 327-332. DOI |
52 | Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., Hagglof, T., Oliveira, T. Y., Viant, C., Hurley, A., Hoffmann, H. H., Millard, K. G., Kost, R. G., Cipolla, M., Gordon, K., Bianchini, F., Chen, S. T., Ramos, V., Patel, R., Dizon, J., Shimeliovich, I., Mendoza, P., Hartweger, H., Nogueira, L., Pack, M., Horowitz, J., Schmidt, F., Weisblum, Y., Michailidis, E., Ashbrook, A. W., Waltari, E., Pak, J. E., Huey-Tubman, K. E., Koranda, N., Hoffman, P. R., West, A. P., Jr., Rice, C. M., Hatziioannou, T., Bjorkman, P. J., Bieniasz, P. D., Caskey, M. and Nussenzweig, M. C. (2020) Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals. bioRxiv doi: 10.1101/2020.05.13.092619. DOI |
53 | Santos, R. A., Ferreira, A. J. and Simoes E Silva, A. C. (2008) Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp. Physiol. 93, 519-527. DOI |
54 | Andrews, S. M. and Rowland-Jones, S. (2017) Recent advances in understanding HIV evolution. F1000Res 6, 597. DOI |
55 | Bernstein, K. E., Khan, Z., Giani, J. F., Cao, D. Y., Bernstein, E. A. and Shen, X. Z. (2018) Angiotensin-converting enzyme in innate and adaptive immunity. Nat. Rev. Nephrol. 14, 325-336. DOI |
56 | Brisse, M., Vrba, S. M., Kirk, N., Liang, Y. and Ly, H. (2020) Emerging concepts and technologies in vaccine development. Front. Immunol. 11, 583077. DOI |
57 | Adams, E. R., Ainsworth, M., Anand, R., Andersson, M. I., Auckland, K., Baillie, J. K., Barnes, E., Beer, S., Bell, J. I. and Berry, T. (2020) Antibody testing for COVID-19: a report from the national COVID scientific advisory panel. Wellcome Open Res. 5, 139. DOI |
58 | Jouan, Y., Guillon, A., Gonzalez, L., Perez, Y., Ehrmann, S., Ferreira, M., Daix, T., Jeannet, R., Francois, B., Dequin, P. F., SiTahar, M., Baranek, T. and Paget, C. (2020) Functional alteration of innate T cells in critically ill Covid-19 patients. medRxiv doi: 10.1101/2020.05.03.20089300 [Online ahead of print]. DOI |
59 | Iskander, J., Haber, P. and Murphy, T. (2004) Suspension of rotavirus vaccine after reports of intussusception-United States, 1999. MMWR Morb. Mortal. Wkly Rep. 53, 786-789. |
60 | Jamilloux, Y., Henry, T., Belot, A., Viel, S., Fauter, M., El Jammal, T., Walzer, T., Francois, B. and Seve, P. (2020) Should we stimulate or suppress immune responses in COVID-19? Cytokine and anticytokine interventions. Autoimmun. Rev. 102567. |
61 | Kabbani, N. and Olds, J. L. (2020) Does COVID19 infect the brain? If so, smokers might be at a higher risk. Mol. Pharmacol. 97, 351-353. DOI |
62 | Keshavarzi Arshadi, A., Webb, J., Salem, M., Cruz, E., Calad-Thomson, S., Ghadirian, N., Collins, J., Diez-Cecilia, E., Kelly, B., Goodarzi, H. and Yuan, J. S. (2020) Artificial intelligence for COVID-19 drug discovery and vaccine development. Front. Artif. Intell. 3, 65. DOI |
63 | Kim, D., Lee, J. Y., Yang, J. S., Kim, J. W., Kim, V. N. and Chang, H. (2020) The architecture of SARS-CoV-2 transcriptome. Cell 181, 914-921.e10. DOI |
64 | Khailany, R. A., Safdar, M. and Ozaslan, M. (2020) Genomic characterization of a novel SARS-CoV-2. Gene Rep. 19, 100682. DOI |